0001493152-23-024164.txt : 20230711 0001493152-23-024164.hdr.sgml : 20230711 20230711082259 ACCESSION NUMBER: 0001493152-23-024164 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230711 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230711 DATE AS OF CHANGE: 20230711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cingulate Inc. CENTRAL INDEX KEY: 0001862150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 863825535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40874 FILM NUMBER: 231081242 BUSINESS ADDRESS: STREET 1: 1901 W. 47TH PLACE CITY: KANSAS CITY STATE: KS ZIP: 66205 BUSINESS PHONE: (913) 942-2300 MAIL ADDRESS: STREET 1: 1901 W. 47TH PLACE CITY: KANSAS CITY STATE: KS ZIP: 66205 8-K 1 form8-k.htm
0001862150 false 0001862150 2023-07-11 2023-07-11 0001862150 CING:CommonStockParValue0.0001PerShareMember 2023-07-11 2023-07-11 0001862150 CING:WarrantsExercisableForOneShareOfCommonStockMember 2023-07-11 2023-07-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 11, 2023

 

CINGULATE INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40874   86-3825535
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

1901 W. 47th Place        
Kansas City, KS       66205
(Address of principal executive offices)       (Zip Code)

 

(913) 942-2300

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   CING  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Warrants, exercisable for one share of common stock   CINGW  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On July 11, 2023, Cingulate Inc. (the “Company”) issued a press release announcing positive top-line results from its Phase 3 adult efficacy and safety trial of its lead candidate, CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity (ADHD), upon approval from the U.S. Food and Drug Administration (FDA). A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 8.01. Other Events.

 

On July 11, 2023, the Company announced positive top-line results from its Phase 3 efficacy and safety trial of its lead candidate, CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD, upon approval from the FDA.

 

The Phase 3 CTx-1301-022 study (NCT05631626), which assessed efficacy and safety along with onset and duration of CTx-1301 in 21 adults (age range: 18-55 years) with ADHD in an adult laboratory classroom setting, demonstrated a meaningful trend in improving ADHD symptoms with a rapid onset of action and entire active-day duration. After a 5-week dose optimization period, subjects were either randomized to their optimized dose of CTx-1301 or placebo. Subjects who were randomized to their optimized dose of CTx-1301 showed improvements on the Permanent Product Measure of Performance (PERMP) (effect size 0.88 to 2.6; with an average of 1.79) compared to subjects randomized to placebo.

 

The overall effect size showed a trend toward significance with a p-value of 0.089 despite the modest sample size. A Meta-Analysis conducted by Faraone and Glatt (Clinical Psychiatry 71:6 June 2010) using 11 published studies with long-acting stimulants in adults demonstrated the average effect size to be 0.73 (approximate range 0.5 to 0.9). Subjects randomized to CTx-1301 demonstrated an effect size of 1.41 at 30 minutes and an effect size of 0.98 at 16 hours. Effect size represents the magnitude of a change in an outcome or the strength of a relationship, the practical significance. The practical significance shows that the effect is large enough to be meaningful in the real world. The larger the effect size the more meaningful the outcome.

 

In addition, the secondary outcome using the Clinical Global Impression (CGI) Scale for severity of illness was associated with a decrease in the severity of illness in subjects randomized to CTx-1301 compared to placebo. This is noteworthy as the purpose of this study was to obtain estimates of effect size and it was not anticipated that significant treatment differences would be observed. CTX-1301 was well tolerated; 9% of the subjects that were randomized to CT-x-1301 experienced treatment emergent adverse events (TEAEs), while 30% of subjects that were randomized to placebo experienced TEAEs. Patient reported outcomes on the overall satisfaction with CTx-1301 compared to subject’s prior ADHD medication was favorable.

 

Full results from the Phase 3 CTx-1301-022 trial, including safety data and patient reported outcomes from a pre- and post-trial questionnaire, are being submitted for presentation at upcoming medical meetings.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release dated July 11, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CINGULATE INC.
     
Dated: July 11, 2023 By: /s/ Shane J. Schaffer
  Name: Shane J. Schaffer
  Title: Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

 

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration

 

KANSAS CITY, KANSAS – July 11, 2023 – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced positive top-line results from its Phase 3 adult trial of its lead candidate, CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).

 

Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator in the Phase 3 CTx-1301-022 who conducted the primary efficacy evaluations, AISRS and PERMP, stated, “From my observation the changes in the Adult ADHD Investigator Symptom Rating Scale (AISRS; a scale that measures aspects of ADHD in adults) demonstrated a positive effect in subjects that received CTx-1301 versus subjects that received placebo. I was also impressed with the overall improvement (change from baseline) of PERMP scores in subjects who were randomized to CTx-1301 compared to placebo. Although a secondary endpoint, the established CGI scale for severity of illness demonstrated clinical improvement in severity of illness. Overall, this in combination with the favorable safety profile, bodes well for future Phase 3 studies.”

 

The Phase 3 CTx-1301-022 study (NCT05631626), which assessed efficacy and safety along with onset and duration of CTx-1301 in 21 adults (age range: 18-55 years) with ADHD in an adult laboratory classroom setting, demonstrated a meaningful trend in improving ADHD symptoms with a rapid onset of action and entire active-day duration. After a 5-week dose optimization period, subjects were either randomized to their optimized dose of CTx-1301 or placebo. Subjects who were randomized to their optimized dose of CTx-1301 showed improvements on the Permanent Product Measure of Performance (PERMP) (effect size 0.88 to 2.6; with an average of 1.79) compared to subjects randomized to placebo.

 

The overall effect size showed a trend toward significance with a p-value of 0.089 despite the modest sample size. A Meta-Analysis conducted by Faraone and Glatt (Clinical Psychiatry 71:6 June 2010) using 11 published studies with long-acting stimulants in adults demonstrated the average effect size to be 0.73 (approximate range 0.5 to 0.9). Subjects randomized to CTx-1301 demonstrated an effect size of 1.41 at 30 minutes and an effect size of 0.98 at 16 hours. Effect size represents the magnitude of a change in an outcome or the strength of a relationship, the practical significance. The practical significance shows that the effect is large enough to be meaningful in the real world. The larger the effect size the more meaningful the outcome.

 

In addition, the secondary outcome using the Clinical Global Impression (CGI) Scale for severity of illness was associated with a decrease in the severity of illness in subjects randomized to CTx-1301 compared to placebo. This is noteworthy as the purpose of this study was to obtain estimates of effect size and it was not anticipated that significant treatment differences would be observed. CTX-1301 was well tolerated; 9% of the subjects that were randomized to CT-x-1301 experienced treatment emergent adverse events (TEAEs), while 30% of subjects that were randomized to placebo experienced TEAEs. Patient reported outcomes on the overall satisfaction with CTx-1301 compared to subject’s prior ADHD medication was favorable.

 

 
 

 

“I’m incredibly proud of our team for reaching this important clinical milestone. This Phase 3 trial is a major validation of what Cingulate has set out to accomplish: create the only ADHD medication that overcomes the major unmet needs of available treatments with clear and unmatched differentiation,” said Shane J. Schaffer, PharmD, Chairman and CEO, Cingulate. “We believe that the analysis of the full data set from this trial, along with completing our two upcoming trials in pediatric and adolescent patients, will allow us to submit a New Drug Application for CTx-1301 by mid-2024, and most importantly, provide patients, physicians, and payors a product that can provide exceptional ADHD treatment.”

 

Full results from the Phase 3 CTx-1301-022 trial, including safety data and patient reported outcomes from a pre- and post-trial questionnaire, are being submitted for presentation at upcoming medical meetings.

 

In addition to the Phase 3 adult dose-optimization study, Cingulate plans to initiate its pivotal Phase 3 fixed-dose pediatric and adolescent study this month and a dose-optimization onset and duration trial in pediatric patients in August 2023. Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit a New Drug Application (NDA) for CTx-1301 in mid-2024 under the Section 505(b)(2) pathway.

 

About Attention Deficit/Hyperactivity Disorder (ADHD)

 

ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. Among this group, approximately 80 percent receive treatment, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), almost double the size of the child and adolescent segment combined, however, only an estimated 20 percent receive treatment.

 

About the CTx-1301 Phase 3 Adult Dose-Optimization Study

 

The first Phase 3 study (CTx-1301-022, NCT05631626) for CTx-1301 was a single-center, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy and safety adult laboratory classroom (ALC) study of CTx-1301 in 21 adults (age range: 18-55 years) with ADHD. The study was comprised of a screening period, a dose-optimization phase, a double-blind randomized phase, and a seven-day safety follow-up period. Subjects underwent a screening visit prior to entering a five-week dose-optimization phase.

 

During the dose-optimization phase, subjects had weekly visits and were titrated to doses ranging between 25 mg and 50 mg of CTx-1301. Cingulate utilized an ALC, which enabled it to facilitate repeated assessments over the course of a day to evaluate the onset and duration of efficacy provided by CTx-1301. Eligible subjects were randomized to their optimal dose or placebo in a 1:1 ratio after completing a practice visit with four Product Measure of Performance (PERMP) assessments. Subjects took their assigned/randomized dose over the following seven-day period. On the seventh day, subjects completed a full ALC visit. The duration of the full ALC visit was approximately 17 hours. Subjects had an in-clinic safety follow-up visit within seven days after the full ALC visit.

 

 
 

 

The primary objective of CTx-1301-022 was to evaluate the efficacy of CTx-1301 compared to placebo in treating adults with ADHD in an ALC study. Secondary objectives included determination of the onset and duration of clinical effect of CTx-1301 in treating ADHD in adults in an ALC study and to determine safety and tolerability of CTx-1301 compared to placebo. The study also evaluated the quality and satisfaction of prior medication to CTx-1301. The Phase 3 clinical trial program for CTx-1301 is being conducted in the U.S. and is instrumental for the filing of the NDA to the FDA, expected in mid-2024.

 

About CTx-1301

 

Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior.

 

While stimulants are the gold-standard of ADHD treatment due to their efficacy and safety, the long-standing challenge remains, providing patients entire active-day duration of action. CTx-1301 is designed to precisely deliver three releases of medication at the predefined time, ratio, and style of release to optimize patient care in one tablet. The result is a rapid onset and entire active-day efficacy, with the third dose being released around the time when other extended-release stimulant products begin to wear off.

 

About Precision Timed Release™ (PTR™) Platform Technology

 

Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma.

 

Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate’s PTR Platform click here.

 

About Cingulate Inc.

 

Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.

 

 
 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature.

 

These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 10, 2023. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

 

# # #

 

Investor Relations:       Media Relations
Matt Kreps  

Thomas Dalton

   Melyssa Weible
Darrow Associates   Vice President, Investor & Public   Elixir Health Public Relations
mkreps@darrowir.com  

Relations, Cingulate

   mweible@elixirhealthpr.com
(214) 597-8200  

tdalton@cingulate.com

   (201) 723-5805
   

(913) 942-2301

    

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 cing-20230711.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 cing-20230711_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 cing-20230711_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, par value $0.0001 per share Warrants, exercisable for one share of common stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 cing-20230711_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 11, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 11, 2023
Entity File Number 001-40874
Entity Registrant Name CINGULATE INC.
Entity Central Index Key 0001862150
Entity Tax Identification Number 86-3825535
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1901 W. 47th Place
Entity Address, City or Town Kansas City
Entity Address, State or Province KS
Entity Address, Postal Zip Code 66205
City Area Code (913)
Local Phone Number 942-2300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $0.0001 per share  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CING
Security Exchange Name NASDAQ
Warrants, exercisable for one share of common stock  
Title of 12(b) Security Warrants, exercisable for one share of common stock
Trading Symbol CINGW
Security Exchange Name NASDAQ
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001862150 2023-07-11 2023-07-11 0001862150 CING:CommonStockParValue0.0001PerShareMember 2023-07-11 2023-07-11 0001862150 CING:WarrantsExercisableForOneShareOfCommonStockMember 2023-07-11 2023-07-11 iso4217:USD shares iso4217:USD shares 0001862150 false 8-K 2023-07-11 CINGULATE INC. DE 001-40874 86-3825535 1901 W. 47th Place Kansas City KS 66205 (913) 942-2300 false false false false Common Stock, par value $0.0001 per share CING NASDAQ Warrants, exercisable for one share of common stock CINGW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cingulate/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm cing-20230711.xsd cing-20230711_def.xml cing-20230711_lab.xml cing-20230711_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "cing-20230711_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "cing-20230711_lab.xml" ] }, "presentationLink": { "local": [ "cing-20230711_pre.xml" ] }, "schema": { "local": [ "cing-20230711.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 2, "memberStandard": 0, "nsprefix": "CING", "nsuri": "http://cingulate/20230711", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-07-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://cingulate/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-07-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "CING_CommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001 per share" } } }, "localname": "CommonStockParValue0.0001PerShareMember", "nsuri": "http://cingulate/20230711", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "domainItemType" }, "CING_WarrantsExercisableForOneShareOfCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, exercisable for one share of common stock" } } }, "localname": "WarrantsExercisableForOneShareOfCommonStockMember", "nsuri": "http://cingulate/20230711", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cingulate/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-024164-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-024164-xbrl.zip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